| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RARg |
| Uniprot No | P13631 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-454aa |
| 氨基酸序列 | MATNKERLFA AGALGPGSGY PGAGFPFAFP GALRGSPPFE MLSPSFRGLG QPDLPKEMAS LSVETQSTSS EEMVPSSPSP PPPPRVYKPC FVCNDKSSGY HYGVSSCEGC KGFFRRSIQK NMVYTCHRDK NCIINKVTRN RCQYCRLQKC FEVGMSKEAV RNDRNKKKKE VKEEGSPDSY ELSPQLEELI TKVSKAHQET FPSLCQLGKY TTNSSADHRV QLDLGLWDKF SELATKCIIK IVEFAKRLPG FTGLSIADQI TLLKAACLDI LMLRICTRYT PEQDTMTFSD GLTLNRTQMH NAGFGPLTDL VFAFAGQLLP LEMDDTETGL LSAICLICGD RMDLEEPEKV DKLQEPLLEA LRLYARRRRP SQPYMFPRML MKITDLRGIS TKGAERAITL KMEIPGPMPP LIREMLENPE MFEDDSSQPG PHPNASSEDE VPGGQGKGGL KSPA |
| 预测分子量 | 50,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于RARγ(RARg)重组蛋白的参考文献，按研究领域分类概括：
---
1. **文献名称**: *"Expression and purification of recombinant human retinoic acid receptor gamma (RARγ) in Escherichia coli for structural studies"*
**作者**: Smith J, et al.
**摘要**: 该研究报道了人源RARγ配体结合结构域(LBD)在大肠杆菌中的高效表达和纯化方法，并通过X射线晶体学解析其三维结构，揭示了与视黄酸类似物的结合模式，为靶向药物设计提供结构基础。
---
2. **文献名称**: *"Development of a luciferase reporter assay system using RARγ recombinant protein to screen selective modulators"*
**作者**: Tanaka K, et al.
**摘要**: 研究团队利用昆虫细胞表达系统制备功能性RARγ重组蛋白，结合荧光素酶报告基因构建高通量筛选平台，成功鉴定出多个选择性调控RARγ活性的小分子化合物，潜在应用于代谢性疾病治疗。
---
3. **文献名称**: *"Functional characterization of RARγ mutants in acute promyelocytic leukemia using recombinant protein models"*
**作者**: Chen L, et al.
**摘要**: 通过体外重组表达白血病相关RARγ突变体，分析其与DNA结合及共激活因子相互作用的异常机制，揭示突变导致转录失调和细胞分化阻滞，为APL的靶向治疗提供新见解。
---
**备注**：以上文献信息为示例性概括，实际引用时需核实具体论文的准确性。建议通过PubMed或Web of Science以关键词“RARgamma recombinant protein”检索最新或高影响力研究。
RARγ (Retinoic Acid Receptor Gamma) is a member of the nuclear receptor superfamily that plays a critical role in regulating gene expression in response to retinoic acid, a metabolite of vitamin A. As a ligand-dependent transcription factor, RARγ forms heterodimers with retinoid X receptors (RXRs) to bind specific DNA sequences, known as retinoic acid response elements (RAREs), in the promoter regions of target genes. This interaction modulates cellular processes such as differentiation, proliferation, and apoptosis, with particular significance in embryonic development, immune function, and tissue homeostasis.
The recombinant RARγ protein is engineered through molecular cloning techniques, typically expressed in bacterial or mammalian systems to ensure proper folding and post-translational modifications. Its structure includes conserved domains: a DNA-binding domain (DBD) for target recognition, a ligand-binding domain (LBD) that interacts with retinoic acid or synthetic ligands, and a hinge region facilitating conformational changes upon ligand binding. Recombinant RARγ is widely used in biochemical and pharmacological studies to investigate receptor-ligand interactions, screen for therapeutic compounds, and decipher signaling pathways.
In disease contexts, dysregulation of RARγ has been linked to cancers, inflammatory disorders, and metabolic syndromes. For example, aberrant RARγ activity is implicated in acute promyelocytic leukemia (APL), where chromosomal translocations generate oncogenic fusion proteins. Recombinant RARγ serves as a tool to study these mechanisms and develop targeted therapies, including synthetic retinoids or selective receptor modulators. Its applications extend to structural biology (e.g., crystallography) and high-throughput drug discovery, highlighting its versatility in both basic research and translational medicine.
×
